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Background: Controversy remains regarding the use of covered stents in congenital heart disease (CHD). We
evaluate the possibilities and safety of covered Cheatham-Platinum (CCP) stents in CHD.
Methods: Single-center retrospective CHD-database study of all CCP stents, 2003–2012. Three study groups:
aortic coarctation (CoA), right ventricular outflow tract pre-stenting for percutaneous revalvulation (RVOT),
and miscellaneous. Continuous data expressed as median (range).
Results: 114 CCP stents in 105 patients, age 16.8 years (4.2–71.2).
CoA group: 54 CCP stents in 51 patients: 3/54 for aneurysm exclusion, in 51/54 covering used “prophylac-
tically” because of increased risk for vessel tear. Overall, CCP stenting increased the coarctation diameter
from 6 mm (0–15) to 15 mm (10–20) (p b 0.001).
RVOT group: 39 CCP stents in 37 patients (34 with RVOT graft, 3 with transannular patch): the graft lumen
had shrunken from nominal 21mm (10–26) to 13mm (5–22); with the CCP stent the RVOTwas redilated to
22 mm (16–26, p b 0.001 vs stenosis).
Miscellaneous group: 21 CCP stents in 17 patients: closure of Fontan-circuit fenestration (n = 5), restora-
tion of superior caval vein (n= 2) or pulmonary artery (n=3) patency, relief of supra-pulmonary stenosis
(n = 2), exclusion of aberrant pulmonary arteries (n = 1), cavopulmonary conduit expansion (n = 2),
Blalock–Taussig shunt flow reduction (n = 1), and defibrillator lead protection from sharp stents (n =
1). Hybrid procedures performed in 3/17 patients. CCP stent was used as rescue treatment in 2/patients
to seal iatrogenic bleeding.
Conclusion: CCP stents can safely be applied in CHD patients. The covering allows adequate sealing of
existing or expected tears, thereby increasing the safety margin with more complete dilation.© 2014 Elsevier Ireland Ltd. All rights reserved.1. Introduction
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Use of covered Cheatham-Plaformation and rupture. The former problem can be addressed by
the use of bare stents, whereas the latter may be overcome by cov-
ered stents [1,2].
Covered stents have been used to treat coarctation of the aorta (CoA)
since 1999 [3]. Despite the growing experience, controversy remains re-
garding indications, effectiveness and safety. Covered stents can be ap-
plied as “rescue” treatment in case of bleeding or aneurysm formation
during percutaneous interventions. An increasing number of covered
stents are used for primary treatment of CoA, re-CoA, and CoA with an-
eurysm formation [4–7], for stenting the right ventricular outflow tract
(RVOT) prior to percutaneous revalvulation [8], and in miscellaneous
conditions such as pulmonary artery stenosis, caval vein obstruction,
Fontan-circuit obstruction and closure of Fontan-circuit fenestrations
[5,9–11].
In this study, we present the various indications, effectiveness and
complications of all covered Cheatham Platinum (CCP, Numed Inc.,tinum stents in congenital heart disease, Int J Cardiol (2014), http://
2 W.Y. Vanagt et al. / International Journal of Cardiology xxx (2014) xxx–xxxHopkinton, NY, USA) stents used in patients with congenital heart dis-
ease (CHD) in our center.
2. Methods
2.1. Study design, study groups and outcome parameters
Retrospective single-center database study of the Pediatric and Congenital Cardiology
database, University Hospital Gasthuisberg Leuven, Belgium. All consecutive CCP stents
implanted in CHD patients from October 2003 until June 2012 were included. The study
complies with the Declaration of Helsinki, and was conducted following the institutional
review board and ethical committee guidelines. Informed consent was waived.
Patientswere divided in 3 groups: coarctation of the aorta (CoA), stenting of the RVOT
prior to percutaneous valve implantation (RVOT), and miscellaneous group. Within each
group, indication was considered to be either prophylactic (procedures at risk for vessel
trauma, presence of sharp calcifications) or therapeutic (exclusion of an acute or chronic
aneurysm, rescue use in case of bleeding during intervention). Effectiveness and occur-
rence of complicationswere assessed. Since CCP stents require larger sheaths as compared
with bare stents [9], each patient file was searched for occurrence of vessel occlusion,
bleeding, limb ischemia, and abnormal peripheral pulsations.
The diameter of the aortic coarctation and peak-to-peak gradient (CoA group) and the
diameter of the RVOT graft (RVOT group) prior to and following stenting or re-dilation
were investigated.
2.2. Stent characteristics
The CCP stent frame is made from 90% platinum and 10% iridium 0.013″wire, welded
in a zig pattern with additional gold soldering. The strut thickness is slightly larger than
most other stents, but makes the stent edges relatively atraumatic [1]. The expanded
poly-tetra-fluoro-ethylene (ePTFE) covering can be dilated up to 26 mm before tearing
[4,12]. The ePTFE is glued at 0° and 180°at each end of the stent; the covering can slide
mildly around the stent during expansion, thereby uncovering the distal tips for 1–
3mmat 90° and 270° (Fig. 1). The stent conformability allows the ends to be flared around
the target lesion or into a bifurcation. The wire thickness and ePTFEmembrane result in a
final thickness of 2–3 Fwhen crimping on a balloon [9]. The stent can be crimped down to
a profile of 10 F leaving a lumen for a 7 F profile balloon. CCP stents are currently CE-
approved in lengths of 16, 22, 28, 34, 39, and 45mm(nonCE-approved for 55 and 65mm).
2.3. Catheterization technique
All procedures were performed under general anaesthesia. Cook sheaths (Cook
Medical Europe, Bjaeverskov, Denmark) were used in all subjects except in the hybrid
procedures. Heparin was administered intravenously (100 IU/kg, maximum 5000 IU).
After wire positioning, hemodynamic measurements and angiography, a long sheath
of appropriate size was positioned. Stent length was chosen to cover the entire length of
the lesion, if possiblewith both ends of the stent reaching “healthy” tissue, thereby sealing
any expected tear at both ends. The CCP stent was hand-crimped on a balloon-in-balloon
(BIB, Numed, Hopkinton, NY, USA). A short (±5 cm) cut-off sheath was used for final
crimping and to facilitate introduction through the sheath's valve. Hand-inflation of the
balloon was performed with a 10 ml syringe on the inner balloon and 20 ml syringe on
the outer balloon, automatically limiting inflation pressures to 4–6 atmospheres. Control
angiography was performed after stent placement, pressure measurements and dimen-
sions were re-evaluated.
The stenting procedurewas technically split into four different aspects: 1] stent deliv-
ery, 2] sealing of the anticipated tear by additional flaring if indicated, 3] securing side ves-
sel patency when needed, and 4] dilation of the stenosis. In a simple discrete lesion in a
large patient all four aspects were treated with 1 balloon. For more complex lesions or
in small patients, several balloons may be required. When sheath size was critical, aFig. 1. Covered Cheatham Platinum stent. Above: crimped. Below: expanded.
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by wrapping it across the stenosis, without aiming at full dilation at initial implantation.
When significant curves were needed to be taken, mild inflation of the outer balloon
was used to create “shoulders”: anterior shoulder allows to un-kink a sheath; posterior
shoulder avoids the stent sliding off the balloon. If sealing the expected tear was essential,
a larger balloon or 2 kissing balloonswere used to flare the stent. In patientswhere sealing
was required at a vessel bifurcation, the stent was delivered using a dual wire technique
and subsequently molded into the bifurcation using a kissing balloon technique [7]. If a
critical structure might be compressed during dilation, progressive incremental dilation
was performed using different balloons.
In case of proximity between the stent and the coronary arteries, test balloon dilation
with simultaneous coronary arteriography was performed to exclude coronary compres-
sion prior to stent delivery.
If a large tear or homograft fracture was expected, the operator preferred stent in-
growth/adhesion for several weeks to maximize sealing before proceeding to final stent
dilation.
When the RVOT had sharp calcifications causing premature rupture of the pre-
dilation balloon, a covered stent was used for “delivery balloon protection”.
Heparin was neutralized by protamine after the procedure when activated clotting
time was N210 s. Hemostasis was obtained using adequate manual compression (taking
10 min of additional anesthesia when necessary), compression during extubation, and
compressive dressing until the next morning. No sutures were used. Anticoagulation
and/or anti-aggregation medication was not routinely prescribed except when stents
were implanted in Fontan circuits or in complex shunts.
2.4. Hybrid procedures
In 3 patients in the miscellaneous group, 5 CCP stents were delivered through
sternotomy in a hybrid surgical suite with monoplane high resolution fluoroscopy. The
hybrid procedures consisted of creation of a sutureless connection to hypoplastic distal
pulmonary arteries (n=2) and of sealing off aortic orifices of aberrant pulmonary arteries
(n= 1).
3. Statistical methods
Continuous data are expressed as median (minimum maximum
range). Prevalence is reported as number and percentages. Comparative
statisticswere donewhere applicable. Since the datawere not normally
distributed, the non-parametric Wilcoxon signed rank test was used.
Two sided p b 0.05was considered significant. Statistic analysiswas per-
formedwith IBM-SPSS version 19 software (SPSS Inc., Chicago, IL, USA).
4. Results
Overall, 114 CCP stents were implanted in 105 patients, 67% male,
age 16.8 years (4.2–71.2). After stent deployment, there was no evi-
dence of any contrast extravasation over the stent course. CCP stent
length, balloon diameter, radiation exposure and fluoroscopy time are
depicted in Table 1.
4.1. CoA group
Fifty-four CCP stents were deployed in 51 patients with CoA, 75%
male, age 19 (8–69) years. In 48/51 patients, the choice for a covered
stentwas “prophylactic”, whereas in 3/51 patients the CCP stent was in-
dicated to exclude a chronic aneurysm [31 years after coarctectomy,
4.5 years after primary CCP stent placement (see below), and 2 years
after simple balloon dilatation]. In 35/51 patients (69%) CCP stenting
was the first intervention, while medical history included previous
coarctectomy in 11/51 (21%) and balloon angioplasty in 5/51 (10%) pa-
tients. In 18/51 patients (35%), the coarctation consisted of a pinpoint
lesion that was passed retrogradely. Five patients (10%) had functional
interrupted aortic arch with a hair-like communication to the descend-
ing aorta requiring antegrade passage, creating a brachial–femoral ar-
tery rail using a snare, followed by retrograde access for stenting. One
patient had an interrupted aortic arch that was punctured through left
radial artery access.
The diameter of the aorta increased at the stent implantation proce-
dure from 6 (0–15) to 14 (7–20) mm (p b 0.001) while peak-to-peak
gradient decreased from 23 (0–86) to 4 (0–25) mm Hg (p b 0.001).
In 30/51 subjects (59%), peak-to-peak gradient was b5 mm Hgtinum stents in congenital heart disease, Int J Cardiol (2014), http://
Table 1
Catheterization data.
Group n Stent length (mm) Balloon diameter (mm) Sheath size (F) Radiation exposure (μGym2) Fluoroscopy time (min)
CoA 51 39 (22–55) 16 (10–20) 12 (10–14) 7492 (1259–47,000) 11 (4–33)
RVOT 37 39 (28–55) 22 (18–24) 14 (12–16) 8842 (659–64,211) 17 (7–73)
Misc 17 34 (28–45) 16 (12–32) 12 (11–16) 9290 (1581–32,950) 18 (7–44)
n: number of patients, CoA: coarctation of the aorta group, RVOT: right ventricular outflow tract pre-stenting group, Misc: miscellaneous group. Data expressed as median (range).
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single procedure was performed. In 12/51 patients (24%), further dila-
tion of the stentwas performed after 4.5 (1.6–28)monthswhere the di-
ameter of the aorta increased from 10 (6–14) to 15 (11–19) mm (p=
0.002) while the peak gradient further decreased from 19 (12–26) to 1
(0–6) mm Hg (p = 0.005). As compared with pre-implantation data,
the overall result at the latest catheterization (either the implantation
procedure or the re-dilation procedure) showed an increase in aortic
diameter from 6 (0–15) to 15 (10–20) mm (p b 0.001) while the
peak-to-peak gradient decreased from 23 (0–86) to 2 (0–25) mm Hg
(p b 0.001).
In one patient, a second CCP stent was inserted during a separate
procedure for late aneurysm formation at the cranial end of the CCP
stent. This patient originally had a pinpoint coarctation close to the ori-
gin of the left subclavian artery, treated with primary CCP stent place-
ment at the age of 13 years using a conventional 1 balloon technique,
leaving the cranial end of the stent in the hypoplastic part of the aortic
isthmus. During full expansion of the stent 4 months later, a tear at
the cranial margin of the stent occurred, progressing to an aneurysm.
A second CCP stent was inserted 4 years later to exclude this aneurysm.
In one patient with the left subclavian artery orifice in the coarcta-
tion, the coarctationwas stented across the left subclavian artery orifice,
followed by retrograde puncture of the CCP stent to restore antegrade
left subclavian artery flow (Fig. 2) [6].
There was no acute bleeding, aneurysm formation or life-
threatening complication. Procedure-related complications included
groin hematoma (n = 3), transient nodal rhythm (n = 1, no wireFig. 2. Coarctation treatment in 10 year-old girl. A: Aortogram shows coarctation at the level o
balloon is positioned through an 11 F sheath; C: deployment of stent; D: aortogram shows excl
rograde perforation of covering of CCP with back-end of 0.035″wire; G: dilation of the punctur
and distal end; no residual gradient, ready for further expansion later after somatic growth.
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nodal escape rhythm (n= 1, while wire was present in left ventricle).
During follow-up no stent fractures, nor stent recompression occurred,
and none of the patients had limb ischemia or signs of vessel occlusion
at the puncture site.
Post-procedural chest pain requiring additional diagnostics (CT scan
and/or echocardiography) to exclude an acute complication occurred in
8/51 patients (16%), responded well to analgesics and subsided within
24 h in all subjects.4.2. RVOT group
Thirty-nine CCP stents were implanted in 37 patients prior to percu-
taneous revalvulation of the RVOT, 70% male, age 16 (6–43) years. An
RVOT cryopreserved homograft (European Homograft Bank EHB,
Brussels, Belgium)was present in 27/37 (73%) of patients, 7/37 patients
(19%) had a Venpro graft (Medtronic Inc., Santa Ana, CA, USA) and 3/37
patients (8%) had a transannular patch.
A CCP stent was chosen for delivery balloon protection after rupture
of the pre-dilation balloon in 7/37 patients (19%). In the remaining 30/
37 patients (81%) a CCP stent was chosen because tear, rupture, or frac-
ture of the conduit was expected, or further stent expansion following
somatic growth was anticipated. Covering the region most at risk for
vessel injury required 2 CCP stents (39 and/or 45 mm) inserted tele-
scopically in 2/37 patients (5%) and placement of a long custom-made
55 mm CCP stent in 3/37 patients (8%).f the left subclavian artery (LSA) orifice; B: a 45 mm CCP stent mounted on a 16 mm BIB
usion of LSA; E: arteriogram LSA through 4 F catheter to guide retrograde puncture; F: ret-
e hole with 8 mm balloon; H: antegrade flow to LSA is restored; stent is flared at proximal
tinum stents in congenital heart disease, Int J Cardiol (2014), http://
Fig. 3. Lateral projection images from catheterization in a 15-year old patient with Tetralogy of Fallot, pulmonary atresia and stenosed calcified 13mm (nominal) RVOT homograft (A, B).
CCP stent in the RVOT at the end of the delivery procedure, the stent was intentionally incompletely dilated at 16mm (C). Additional placement of a bare stent proximally in the CCP stent
with dilation of both stents to 22 mm during a second procedure after 2 months (D).
4 W.Y. Vanagt et al. / International Journal of Cardiology xxx (2014) xxx–xxxCCP stenting and RVOTpercutaneous valve deliverywere performed
in a single procedure in 22/37 subjects (59%), whereas CCP stent re-
dilation with percutaneous revalvulation was achieved during a second
procedure in 15/37 patients (41%) after 61 (40–146) days (Fig. 3).
When necessary, an additional bare stent was inserted [11 bare
stents in 10/37 (27%) patients] until the conduit became a rigid tube
without external compression in order to obtain minimal gradient
prior to percutaneous revalvulation. The nominal graft diameter
(diameter at graft insertion, n= 34) was 21 (10–26) mm, stenosed to
13 (5–22) mm (p b 0.001 versus nominal size), and increased to 22
(16–26) mm prior to revalvulation (p = 0.035 versus nominal size
and p b 0.001 versus graft stenosis). Dilation beyond the “nominal”
graft diameter was performed in 16/34 patients (47%), with the percu-
taneous valve size 2 (1–9) mm larger than the nominal graft size.
There were no procedure-related complications and no extravasa-
tion. Neither embolization nor fracture of CCP stents was found on an-
nual chest X-ray follow-up.
4.3. Misc group
Twenty-one CCP stents were implanted in 17 subjects [53% male,
age 13 (4–71) years]. Indication for CCP stenting consisted of Fontan-
circuit fenestration closure (n = 5), restoration of superior caval vein
(n = 2) or pulmonary artery (n = 3) patency, relief of supra-
pulmonary stenosis after arterial switch operation (n = 2), sealing of
aberrant pulmonary artery orifices (n=1), cavopulmonary conduit ex-
pansion (n=2), Blalock–Taussig shunt flow reduction (n=1) and de-
fibrillator lead protection during percutaneous re-revalvulation of a
prosthetic tricuspid valve (n = 1). In 3/17 abovementioned subjects
(15%), 5 CCP stents were delivered during hybrid procedures (Fig. 4).Fig. 4.A: Antero-posterior projection, result of hybrid procedure at 13.5 years of age in a patient
with a bilateral 5 mm Blalock–Taussig shunt): bilateral CCP stents to connect the Gore-Tex cen
artery and Blalock–Taussig shunt from previous interventions are also visible. B: Contrast injec
Please cite this article as: Vanagt WY, et al, Use of covered Cheatham-Pla
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year old patient, rescue CCP stenting was performed because of dissec-
tion of the left pulmonary artery creating an aortopulmonary window
upon dilation of a Palmaz stent (Cordis Corp., Bridgewater, NJ, USA)
that was positioned 11 years before because of peripheral pulmonary
artery stenosis after arterial switch procedure. In this patient, CCP
stent redilatation 4 years later resulted again in an aorta-pulmonary
window, for which another CCP stent was successfully implanted. The
other patient requiring rescue treatment with a CCP stent had leakage
at the proximal end of a stent upon placement in the left pulmonary ar-
tery during a hybrid procedure. During follow-up, there were no stent
fractures and no recompression.
5. Discussion
This report describes a 9 year experiencewith CCP stents as a valuable
tool in the management of patients with simple and complex congenital
heart disease. The addition of a covering around a stent allows safer and
more complete dilatation of stenotic lesions, with a better expected long-
term outcome. Moreover, the miscellaneous use of a covered stent per-
mits procedures previously considered un-achievable by creating [13],
excluding [11], enlarging [1,14] or restricting vessel segments.
5.1. Optimal results through more complete dilatation
Bare stents do offer an answer to complications of balloon dilation
such as recoil and dissection, and diminish the risk for aneurysm forma-
tion and vessel tear by no longer requiring overdilation [15]. However,
aortic wall complications with bare stenting still occurred in 3.9% of
565 procedures [16]. The highest risk is when a significant increase inwith pulmonary atresia, absent pulmonary artery stemand bifurcation (treated neonatally
tral shunt and bifurcation to the distal pulmonary arteries. Stents in the right subclavian
tion in the central shunt.
tinum stents in congenital heart disease, Int J Cardiol (2014), http://
5W.Y. Vanagt et al. / International Journal of Cardiology xxx (2014) xxx–xxxcircumference is imposed on a poorly compliant or calcified wall. “Con-
servative” stenting of the aorta, while still accepting a mild to moderate
residual gradient, is still at risk for major complications due to a non-
contained tear. Similarly, “conservative” stenting of a narrowed RVOT
conduit up to nominal size frequently leaves a significant gradient, and
nevertheless involves a significant tear with intrathoracic bleeding in
1–3% of patients [17,18]. Our results demonstrate that covered stenting
allows significant expansion of a target lesion to the desired dimension
with no, or minimal gradient, but without any aneurysm or blood ex-
travasation within the stent. Narrow coarctations and an interrupted
aorta could be treated safely with adequate expansion leaving no signif-
icant gradient, while undoubtedly creating major tears in the vessel
wall. Similarly, in patientswith a narrowed RVOTwith orwithout a con-
duit, covered stenting permitted expansion of the RVOT and/or the con-
duit up to and beyond the nominal graft size. This approach aimed to
leave no, or a minimal residual gradient, which then allowed to implant
an adequately sized valved stent. In many patients this dilatation must
have involved significant tearing and fracturing of the conduit. When
created with a bare stent, such tear would result in pericardial, medias-
tinal or pleural bleeding, dependingon the degree of adhesions. By using
a covered stent, an adequate landing zone without extravasation was
obtained. The aim was to cover the whole conduit with the covered
stent even if some parts were not restrictive at implantation, allowing
safer future redilation to accommodate for somatic growth.5.2. Adapted techniques with covered stents
Covered stentswere initially chosen anddeployed as done previous-
ly with bare stents in our center. However a covered stent offers specific
opportunities and limitations which require adapted techniques
(Fig. 5): 1] longer stent for sealing, 2] flare to seal and to reduceflowdis-
turbance, and 3] maintain side-vessel patency.
1] Longer stent for sealing the target: When a tear or rupture is an-
ticipated, the covering typically will impede extravasation. However a
tear may extend until the edge of the diseased tissue, which is typically
until where a bare stent would reach. In order to seal the target lesion at
both ends to obtain extra safety, a longer covered stent is used. The aim
is thus to bridge the target lesion from “healthy to healthy” vessel. Of
note, the covering of a CCP stent does not reach the edges of the stent,
but will retract for a few millimeters during expansion, except for the
2 glued points at each end. When the anatomy allows it, the covered
stent is delivered on a larger balloon to flare the stent at delivery against
the vessel wall, without the aim to dilate the target lesion with the de-
livery balloon. Dilation of the stenosis is subsequently performed with
high pressure balloons. If the sealing needs to be more robust, the cov-
ered stent is left to adhere to the intimal layer for several weeks before
proceeding to further dilatation.We do not consider this a failure of theFig. 5. Cartoon of technical differences bare versus covered stent. A: stenotic lesion in blood ve
cations: aneurysm-tear inmid-lesion, or tear at cranial end with bleeding/aneurysm beyond th
the middle is automatically covered, the tear at the end is sealed by extra length which is flare
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CCP stents. Using this technique, we have never observed extravasation
due to a tear.Whether the same result could be achieved safelywith full
dilation in a single procedure cannot be assessed using our data. In a se-
ries of 13 patients with CoA treated with self-fabricated covered stents,
acute aneurysm formation and rupture occurred once after full balloon
expansion in a single procedure [19].
2] Flaring: this is almost never indicated when using a bare stent.
With covered stents, flaring the stent against the vessel wall may be re-
quired to get an adequate seal. Other reasons toflare a covered stent are
to reduce the overall resistance of the tube graft and to avoid flow vor-
tices that might cause an infolding of the stent.
3] Side vessel patency. When the target lesion is close to a bifurca-
tion, a bare stent may easily be placed across the origin of that side ves-
sel and the stent cells may be dilated if required. A covered stent
requires an adapted strategy for side-vessels such as: stent delivery par-
tially covering the orifice (but still allowing probing of the side-vessel
for subsequent flaring), double wire delivery which guarantees side-
vessel accessibility [7], crossing the side-vessel with the covered stent
and either accept the exclusion, surgically translocate and reimplant
the vessel, or perform a retrograde puncture and dilation (Fig. 2) of
the membrane at the orifice of the side vessel [6].5.3. Prophylactic versus curative use
Some physicians will only implant a covered stent after a proven
complication (aneurysm or non-contained tear) of a bare stent oc-
curred, either by personal preference or because of local regulations
(FDA restriction in USA). A covered stent is then implanted in stressed
conditions as a rescue treatment in a potentially hemodynamically un-
stable patient. A tear in the middle of a narrowing will usually be
shielded easily; however a tear at the edge of a conduit with a pre- or
post stenotic dilation, or at a bifurcationmay be very difficult to control,
as the bare stent will impede adequate flaring of the covered stent over
the tear. We therefore have evolved from “curative” to “prophylactic”
use, not only when an acute tear or fracture of the target lesion is ex-
pected, but also to avoid late aneurysm formation.
Because of the possibility of a tear in themembrane, we always keep
a large covered stent, balloon and sheath available for fast deployment
to add to the safety of the procedure [20].5.4. Interventions possible owing to covered stents
The CCP stent is useful in hybrid procedures to access anatomic loca-
tions that are most difficult to reach surgically. The CCP stent is also an
effective tool in miscellaneous congenital or post-surgical cardiacssel or conduit; B: expansion of bare stent with subtotal expansion, but 2 possible compli-
e zone covered by this stent; C: deployment of a covered stent which is longer; any tear in
d; D: covered stent allows safe near-total expansion of the stenotic segment.
tinum stents in congenital heart disease, Int J Cardiol (2014), http://
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conduit patency, or closure of communications were reached.
5.5. Performance of the membrane
The membrane is designed to stretch without tearing until 26 mm.
Theoretically, a sharp calcified lesion might tear the membrane prema-
turely. We never observed perforations during placement, or aneu-
rysms in the course of the CCP stents, suggesting that membrane
integrity was preserved. When previously still using shorter stents not
reaching “healthy” tissue, we observed one aneurysm at the cranial
end of a stent in CoA during chronic follow-up; this was treated with
an additional CCP stent. Overall, the membrane at the edge of a tear
sealed the lumen very adequately: in obligatory tears (interrupted
arch, hybrid sutureless anastomosis) no extravasation was observed.
Our data confirm that CCP stents can be re-dilated without ePTFE
membrane rupture after somatic growth, or when the CCP stent was
not fully dilated initially [21,22]. We observed one CCP stent tear
when redilating it 4 years after insertion (see results section, miscella-
neous group), where “sandwiching” of the ePTFE membrane between
the outer bare stent and inner CCP stent apparently made the covering
vulnerable for tear.
5.6. Vascular access issues
In comparison with delivery of a bare stent, covered stent insertion
requires a 1–2 F larger sheath size [9], with a minimum sheath size of
10 F.We did not observe significant complications at the vascular access
site. In the typical adolescent and adultwith CoA, a 14 F sheathwas used
and well tolerated.
6. Study limitations
Wedonot routinely performCT scanning to detect aneurysm forma-
tion after CCP stent placement. Therefore, under-reporting of aneurysm
formation cannot be excluded. Furthermore, the long-term formation of
peal in the stent was not assessed.
In this retrospective study, there are no control groups with bare
stents, the lack of which is inherently related to the fact that some of
these procedures would have been impossible, or significantly less
safe, if bare stents were used.
7. Conclusions
CCP stents can safely be applied in a broad range of CHD patients.
The covering allows adequate sealing of existing or expected tears,
thereby increasing the safetymarginwithmore complete dilation in se-
lected patients.Please cite this article as: Vanagt WY, et al, Use of covered Cheatham-Pla
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